Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE, DATED JANUARY 4, 2012 - ISTA PHARMACEUTICALS INC | d276613dex991.htm |
| EX-99.2 - 2012 GUIDANCE AND PIPELINE UPDATE PRESENTATION - JANUARY 2012. - ISTA PHARMACEUTICALS INC | d276613dex992.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 4, 2012
ISTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 000-31255 | 33-0511729 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 50 Technology Drive, Irvine, California | 92618 | |||
| (Address of principal executive offices) | (Zip Code) | |||
Registrant’s telephone number, including area code: (949) 788-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425). |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 2.02 | Results of Operations and Financial Condition. |
On January 4, 2012, ISTA Pharmaceuticals, Inc. (the “Company”) issued a press release to provide preliminary unaudited financial updates for the year ended December 31, 2011 and financial guidance for the year ending December 31, 2012. The release is furnished as Exhibit 99.1 hereto and incorporated herein by this reference.
The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
| Item 7.01 | Regulation FD Disclosure. |
Commencing on January 4, 2012, the Company will utilize an updated presentation for investor relations purposes entitled “2012 Guidance and Pipeline Update.” The updated presentation is furnished as Exhibit 99.2 hereto and incorporated herein by this reference.
The information in this Item 7.01, including Exhibit 99.2, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press release, dated January 4, 2012. | |
| 99.2 | 2012 Guidance and Pipeline Update Presentation – January 2012. | |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ISTA PHARMACEUTICALS, INC. | ||||||||
| January 4, 2012 | By: | /s/ LAUREN P. SILVERNAIL | ||||||
| Chief Financial Officer and Vice President, Corporate Development | ||||||||
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press release, dated January 4, 2012. | |
| 99.2 | 2012 Guidance and Pipeline Update Presentation – January 2012. | |